Impact of New Therapeutic Approaches for the Treatment of Post-Transplant Tumors on the Outcome of the Transplanted Organ

The field of oncology has seen remarkable advancements in therapeutic approaches over the past decade, significantly improving cancer prognosis in the general population. However, solid organ transplantation (SOT) recipients face a unique challenge, as they exhibit a higher incidence of neoplasms compared to non-transplanted individuals, contributing to increased mortality rates post-transplant. This has sparked considerable interest in the potential application of novel oncological therapies within the SOT clinical setting. Despite the promise these new drugs hold, such as VEGF inhibitors, TK- or MultiK-Inhibitors, and immune checkpoint inhibitors (ICI), they present challenges due to their organ-specific toxicities and potential interference with immune system responses (ISR) and ongoing immunosuppressive therapy (IST). This interference could significantly impact both the transplanted organ's and the patient's outcomes. Current research is focused on understanding these interactions and addressing the gaps in knowledge regarding the safe and effective use of these therapies in SOT patients.

This research topic aims to explore the critical aspects of integrating new therapeutic approaches for post-transplant tumors and their impact on the outcomes of transplanted organs. The primary objectives include examining the epidemiological data on neoplasia occurrence in various SOT types, assessing the influence of different ISTs on cancer risk post-transplant, and understanding the effects of post-SOT cancer on graft and patient outcomes. Additionally, the research seeks to clarify how new anti-cancer drugs affect ISR and IST, and to develop strategies for managing these drugs in diverse SOT contexts.

To gather further insights into the impact of new therapeutic approaches on post-transplant tumors and organ outcomes, we welcome articles addressing, but not limited to, the following themes:
- Epidemiological figures for neoplasia occurrence in different SOT types.
- Impact of various ISTs on cancer risk post-SOT.
- Effects of post-SOT cancer on graft and patient outcomes.
- Influence of new anti-cancer drugs on ISR and their interaction with IST.
- Strategies for managing new anti-cancer drugs in different SOT settings.